Literature DB >> 1677827

Phase II trial of taxol in patients with metastatic renal cell carcinoma.

A I Einzig1, E Gorowski, J Sasloff, P H Wiernik.   

Abstract

Based on results of previous Phase I studies, 18 patients with documented metastatic renal cell carcinoma received Taxol 250 mg/m2 as a 24-h infusion, repeated every 21 days in this Phase II study. All patients received premedication with dexamethasone, diphenhydramine, and cimetidine. There were no responses in the 18 patients treated.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1677827     DOI： 10.3109/07357909109044223

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  7 in total

1.  Paclitaxel and docetaxel. Innovation, but at what cost?

Authors:  P E Lønning
Journal:  Pharmacoeconomics       Date:  1995-07       Impact factor: 4.981

2.  A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Authors:  Hui Huang; Michael Menefee; Maureen Edgerly; Sen Zhuang; Herb Kotz; Marianne Poruchynsky; Lyn Mickley Huff; Susan Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 3.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Taxol dose intensification and its clinical implications.

Authors:  G Sarosy; E Reed
Journal:  J Natl Med Assoc       Date:  1993-06       Impact factor: 1.798

Review 5.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

6.  The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.

Authors:  P Nygren; K Csoka; B Jonsson; H Fridborg; J Bergh; H Hagberg; B Glimelius; O Brodin; B Tholander; A Kreuger
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

7.  Cathepsin S Cleaves BAX as a Novel and Therapeutically Important Regulatory Mechanism for Apoptosis.

Authors:  Surinder M Soond; Lyudmila V Savvateeva; Vladimir A Makarov; Neonila V Gorokhovets; Paul A Townsend; Andrey A Zamyatnin
Journal:  Pharmaceutics       Date:  2021-03-05       Impact factor: 6.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.